"Lecanemab"
生产企业：Biogen
Lecanemab is an amyloid beta-targeting antibody used to treat Alzheimer’s Disease in patients with mild cognitive impairment or mild dementia with a known amyloid beta pathology.
Lecanemab is an amyloid beta-targeting antibody used to treat Alzheimer’s Disease in patients with mild cognitive impairment or mild dementia with a known amyloid beta pathology.
Extracellular amyloid-β (Aβ) plaques are a hallmark pathology of Alzheimer's disease (AD), making them a desirable therapeutic target for potential drugs for treating AD. The production and accumulation of Aβ plaques in the brain are commonly observed in AD, and distinct characteristics of Aβ plaques - such as the solubility, quantity, and composition of Aβ pools - may affect the disease state. Aβ causes synaptic impairment, neuronal death, and progressive neurodegeneration, which leads to dementia and cognitive impairment associated with AD. Aβ peptides exist in various conformational states, including soluble monomers, soluble aggregates of increasing size, and insoluble fibrils and plaque. Soluble Aβ aggregates such as Aβ protofibrils are more neurotoxic than monomers or insoluble fibrils. Lecanemab is an antibody that lowers Aβ plaques in the brain. It preferentially targets soluble aggregated Aβ and works on Aβ oligomers, protofibrils, and insoluble fibrils.
Lecanemab is indicated for the treatment of Alzheimer’s disease. Treatment with lecanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
